title: Urticaria after methyl aminolevulinate photodynamic therapy in a patient with nevoid basal cell carcinoma syndrome.
abstract: Methyl aminolevulinate photodynamic therapy (MAL-PDT) is utilized in several countries for the treatment of basal cell carcinoma, but allergic sensitization has been reported by the manufacturer. To the best of our knowledge, we report the first case of urticaria following MAL-PDT in a patient with nevoid basal cell carcinoma syndrome. Prophylactic use of antihistamines may allow continued use of MAL-PDT in this setting.
authors.affiliation: Lake Erie College of Osteopathic Medicine, Erie, PA, USA. wolfe1pa@gmail.com
authors.forename: Christopher M
authors.initials: CM
authors.lastname: Wolfe
authors.forename: W Harris
authors.initials: WH
authors.lastname: Green
authors.forename: H Keith
authors.initials: HK
authors.lastname: Hatfield
authors.forename: Armand B
authors.initials: AB
authors.lastname: Cognetta
mesh_terms: D000622:Aminolevulinic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001478:Basal Cell Nevus Syndrome / Q000188:drug therapy / Q000473:pathology; D002280:Basal Cell Carcinoma / Q000188:drug therapy / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D010778:Photochemotherapy / Q000009:adverse effects* / Q000379:methods; D017319:Photosensitizing Agents / Q000009:adverse effects* / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000188:drug therapy / Q000473:pathology; D014581:Urticaria / Q000209:etiology*
chemical_list: D017319:Photosensitizing Agents; C475457:methyl 5-aminolevulinate; D000622:Aminolevulinic Acid